Neogen® announced today that its genomics business located in Lincoln, Nebraska, has received a CLIA (Clinical Laboratory Improvement Amendments) Certificate of Compliance from the Center for Medicare & Medicaid Services (CMS).
With this certification, Neogen’s genomics laboratory is able to conduct human genotyping, enabling the company to undertake a broad range of clinical research projects and high-throughput genetic variant screening, as well as participate in the interrogation of methylation patterns at the genome-wide level for epigenome-wide association studies.
“Neoge nis continuously operating with a growth mindset and looking for ways to offer new, innovative services and solutions to our customers around the world,” said John Adent, Neogen’s President and CEO. “By earning this CLIA certification, we are able to expand our genomics services into the field of human testing, offering our world-leading services to a variety of new institutions, be involved in new forms of screening, and contribute to research into the human genome.”
“Securing the CLIA certification is a significant accomplishment for Neogen Genomics, our highly-trained lab personnel, and our state-of-the-art facility,” said Dr. Jason Lilly, Neogen’s Vice President of International Business. “With a biological testing laboratory that is CLIA and ISO/IEC 17025:2017 certified, we are able to demonstrate our commitment to achieving the highest quality standards and providing services that our clients can trust.”
The Clinical Laboratory Improvement Amendments of 1988 regulations include federal standards applicable to all U.S. facilities or sites that test human specimens for health assessment or to diagnose, prevent, or treat disease.